Not for human use, medical, or diagnostic applications
In a phase 2 clinical trial for obesity, 26 weeks of efinopegdutide (doses 5 to 10mg) resulted in up to 11.8% WL in people with obesity (without diabetes) compared to 7.5% WL with liraglutide 3 mg and 1.8% WL with placebo [77, 78]
Real-world use involves more diverse patient populations than clinical trials, including individuals with complex medical histories, polypharmacy, and pre-existing mental health conditions
Can gallbladder complications from retatrutide be managed
Frequently Asked Questions How can I tell if my lyophilized Melanotan 2 powder has gone bad
For some, taking these medications is worth it to shed pounds and the stigma of living in a larger body